A Phase 3 interventional study of preservative-free parenteral treprostinil in Pulmonary Arterial Hypertension, sponsored by AOP Orphan Pharmaceuticals AG. Recruiting at 5 sites in 5 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by AOP Orphan Pharmaceuticals AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Pulmonary Arterial Hypertension with a site in Austria — 4 open to participants now, 6 under way, 4 of them phase 3. Pulmonary Arterial Hypertension · Austria.
Among the 54 studies in Pulmonary Arterial Hypertension with a site in Austria, this one is the 46th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2024, is one of 30 in phase 3, and was the 53rd registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →4 of the 54 studies in Pulmonary Arterial Hypertension with a site in Austria are open now. Recruiting first, the newest first:
AOP Orphan Pharmaceuticals AG · Sites in Austria, Argentina, Czechia and 9 more countries
Ages 18–75
AOP Orphan Pharmaceuticals AG · Sites in Austria, Czechia, France and 6 more countries
Ages 18+
United Therapeutics · Sites in Austria, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 33 · Phase 4 4
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 205 across the 48 interventional studies, 98 across the 6 observational. Of the 46 that completed or were terminated, 30 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 54 have an industry lead sponsor. The 10 most frequent:
AOP Orphan Pharmaceuticals AG is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
AOP Orphan Pharmaceuticals AG has 4 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Pulmonary Arterial Hypertension with a site in Austria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT06317805AOP Orphan Pharmaceuticals AGInitial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Pulmonary Arterial Hypertension with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is:
Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week).
In this study, a preservative-free treprostinil solution provided in a single-use vial will be used. Efficacy of treprostinil for the treatment of PAH in pulmonary hypertension (PH) Group 1 in children is reported throughout literature. However, since the removal of the preservative might impact the safe use of the parenteral solution for infusion, the safety profile of the newly developed preservative-free treprostinil solution will be assessed within this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current diagnosis of PAH confirmed by right heart catheterisation (RHC) at screening or by historical RHC prior to screening with following haemodynamic findings:
A subject is eligible to participate in this study, as assessed by the investigator, if they are of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with either SC or IV preservative-free treprostinil formulation. Dosing is not stipulated by the study protocol and will be done according to investigators discretion based on patient needs.
Drug: preservative-free parenteral treprostinil
Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
Frequency and seriousness of adverse events and adverse drug reactions
The frequency and seriousness of adverse events and adverse drug reactions during the first 5 months (20 weeks ± 1 weeks) of treatment according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in quality of Life (QoL)
Change from baseline in quality of Life (QoL) as assessed by the Pediatric Quality of Life Inventory (PedsQoL Version 4.0) questionnaire. Rating from 0 (never) to 4 (almost always) per question. Questionnaire will be completed by pediatric patient (version appropriate for age group) and parents/caregivers.
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in 6-minute walk distance (6MWD)
Change from baseline in 6MWD (patients \> 6 years)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in World Health Organization Functional Class (WHO FC)
Change in WHO FC class assessment based on current PH guidelines ranging from class I to class IV, whereas class IV means severe limitations.
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - RA/RV enlargement
right atrium (RA) / right ventricle (RV)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - RV systolic dysfunction
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - RV/LV end-systolic ratio (PSAX)
RV / left ventricle (LV)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - tricuspid annular plane systolic excursion (TAPSE)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - S/D ratio (TR jet)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - Pulmonary Artery Acceleration Time (PAAT)
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - pericardial effusion
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - eccentricity index
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in echocardiography (ECHO) parameters - acceleration time
Time frame: 5 months (20 weeks ± 1 weeks)
Change from baseline in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels
Time frame: 5 months (20 weeks ± 1 weeks)
Treprostinil plasma concentration
For treprostinil plasma concentration analysis one 0,5 ml blood sample for patients ≤ 20 kg and one 1ml blood (K3-EDTA) sample for patients \> 20kg will be taken.
Time frame: 5 months (20 weeks ± 1 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Nov 2028, 52 months after the start.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 52 months is close to that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
AOP Orphan Pharmaceuticals AG